The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

The new prefilled syringe has the same composition but removes the need for reconstitution, providing a more convenient option for health care providers who administer vaccines. According to the ...

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...

In an investor call, Andrew Witty promised full transparency and 100% pass-through rebates for prescription drugs by 2028.

Jason McLellan, professor in the Department of Molecular Biosciences and Robert A. Welch Chair in Chemistry at UT, will be ...

McLellan, who will be inducted in Washington, D.C. on May 8, is among the youngest new inductees in hall of fame history.

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...